Manufacturing Industry

SHIRE PLC - FDA Approval of prodrug VYVANSE for treatment of ADHD.

PR Newswire UK Disclose, February, 2007

 
Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only 
Stimulant Prodrug VYVANSEao (lisdexamfetamine dimesylate) as a Novel Treatment 
for ADHD 
 
Basingstoke, U.K., Philadelphia, PA and Radford, VA - FEBRUARY 23, 2007 - Shire 
plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River 
Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug 
Administration (FDA) has granted marketing approval for VYVANSE 
(lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of 
Attention Deficit Hyperactivity Disorder (ADHD). 
 
On February 20, 2007 Shire and New River announced an agreement whereby Shire 
will acquire New River for approximately $2.6 billion in an all cash 
transaction unanimously...

            
        
    
    	    
                
                
	
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement